Ginisortamab
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors[1][2][3].
Product Specifications
CAS Number
2390147-17-6
Product Name Alternative
UCB6114
UNSPSC
12352203
Target
Dan family
Type
Inhibitory Antibodies
Related Pathways
TGF-beta/Smad
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ginisortamab.html
Purity
99.05
Solubility
10 mM in DMSO
Smiles
[Ginisortamab]
Molecular Weight
(147.56 kDa)
References & Citations
[1]Debashis Sarker, et al. A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors. Meeting Abstract, 2022 ASCO Gastrointestinal Cancers Symposium.|[2]Davies GCG, et al. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. MAbs. 2023 Jan-Dec;15 (1) :2289681.|[3]Debashis Sarker, et al. Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors. Cancer Res (2023) 83 (8_Supplement) : CT094 .
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K1300604 1.0 µg DNA
MIAT sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details 
abx404262-01 100 µL
Peptidyl Arginine Deiminase Type 4 (PADI4) Antibody
Sign In for Pricing
View Details